Finance

Beta
Lists
AKTS:NASDAQ
Aktis Oncology Inc
$30.11
+2.28%
(+0.67) 1D
$30.11
0.00% (0.00)
After hours
Closed: Jun 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
$29.45
High
$31.92
Low
$29.00
Mkt. cap
1.61B
Avg. vol.
312.45K
Volume
539.26K
52-wk high
$33.53
52-wk low
$14.72
EPS
-$1.34
Shares outstanding
53.40M
No. of employees
79
Open
$29.45
High
$31.92
Low
$29.00
Mkt. cap
1.61B
Avg. vol.
312.45K
Volume
539.26K
52-wk high
$33.53
52-wk low
$14.72
EPS
-$1.34
Shares outstanding
53.40M
No. of employees
79
News stories
From sources across the web
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteaktisoncology.com
Analyst ratings
Based on 5 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current $30.11
$40.00 (+32.85%)
Average
$36.33 (+20.66%)
Lowest
$34.00 (+12.92%)
Analyst
Recommendation
Action
Price target
Projected
Date
Christopher Raymond
Raymond James
Buy
Initiated
$40.00
+32.8%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$35.00
+16.2%
06/03/2026
Alexandra Ramsey
William Blair
Buy
Reiterated
-
-
06/01/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$34.00
+12.9%
05/31/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
$18.75
-37.7%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
$18.60
-38.2%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
$32.00
+6.3%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
$31.00
+3%
02/03/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
$30.00
-0.4%
02/03/2026
Last report
May 11, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.38 / -$0.36
-6.29%miss
Revenue / Est. (USD)
3.23M / 2.31M
+39.55%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Dec 2024
Mar 2025
Dec 2025
Mar 2026
Revenue
933.00K
1.45M
1.87M
3.23M
Cost of goods sold
12.61M
15.86M
16.49M
20.04M
Cost of revenue
12.61M
15.86M
16.49M
20.04M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.96M
3.73M
2.75M
5.90M
Operating expense
3.96M
3.73M
2.75M
5.90M
Total operating expenses
16.57M
19.59M
19.24M
25.93M
Operating income
-15.64M
-18.14M
-17.38M
-22.71M
Other non operating income
-1.00K
-13.00K
-11.00K
-3.00K
EBT including unusual items
-12.06M
-14.98M
-15.14M
-18.32M
EBT excluding unusual items
-12.06M
-14.98M
-15.14M
-18.32M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.06M
-14.98M
-15.14M
-18.32M
Net profit margin
-1,292.18%
-1,035.59%
-809.52%
-567.86%
Earnings per share
-
-
-
-0.38
Interest and investment income
3.58M
3.17M
2.25M
4.38M
Interest expense
-
-
-
-
Net interest expenses
3.58M
3.17M
2.25M
4.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.19M
-17.66M
-16.68M
-22.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer